Literature DB >> 31086254

Treating leukemia: differentiation therapy for mIDH2 AML.

Xiao-Jian Sun1, Sai-Juan Chen2, Zhu Chen3.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31086254      PMCID: PMC6796903          DOI: 10.1038/s41422-019-0173-4

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  10 in total

1.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.

Authors:  Tino Schenk; Weihsu Claire Chen; Stefanie Göllner; Louise Howell; Liqing Jin; Katja Hebestreit; Hans-Ulrich Klein; Andreea C Popescu; Alan Burnett; Ken Mills; Robert A Casero; Laurence Marton; Patrick Woster; Mark D Minden; Martin Dugas; Jean C Y Wang; John E Dick; Carsten Müller-Tidow; Kevin Petrie; Arthur Zelent
Journal:  Nat Med       Date:  2012-03-11       Impact factor: 53.440

Review 2.  Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.

Authors:  Hugues de Thé; Pier Paolo Pandolfi; Zhu Chen
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

Review 3.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

4.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

5.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Authors:  Michael D Amatangelo; Lynn Quek; Alan Shih; Eytan M Stein; Mikhail Roshal; Muriel D David; Benoit Marteyn; Noushin Rahnamay Farnoud; Stephane de Botton; Olivier A Bernard; Bin Wu; Katharine E Yen; Martin S Tallman; Elli Papaemmanuil; Virginie Penard-Lacronique; Anjan Thakurta; Paresh Vyas; Ross L Levine
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

6.  Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.

Authors:  Vera Mugoni; Riccardo Panella; Giulia Cheloni; Ming Chen; Olga Pozdnyakova; Dina Stroopinsky; Jlenia Guarnerio; Emanuele Monteleone; Jonathan David Lee; Lourdes Mendez; Archita Venugopal Menon; Jon Christopher Aster; Andrew A Lane; Richard Maury Stone; Ilene Galinsky; José Cervera Zamora; Francesco Lo-Coco; Manoj Kumar Bhasin; David Avigan; Letizia Longo; John Gerard Clohessy; Pier Paolo Pandolfi
Journal:  Cell Res       Date:  2019-04-25       Impact factor: 46.297

7.  Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.

Authors:  Shuo Wei; Shingo Kozono; Lev Kats; Morris Nechama; Wenzong Li; Jlenia Guarnerio; Manli Luo; Mi-Hyeon You; Yandan Yao; Asami Kondo; Hai Hu; Gunes Bozkurt; Nathan J Moerke; Shugeng Cao; Markus Reschke; Chun-Hau Chen; Eduardo M Rego; Francesco Lo-Coco; Lewis C Cantley; Tae Ho Lee; Hao Wu; Yan Zhang; Pier Paolo Pandolfi; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

8.  Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.

Authors:  Andrew M Intlekofer; Alan H Shih; Bo Wang; Abbas Nazir; Ariën S Rustenburg; Steven K Albanese; Minal Patel; Christopher Famulare; Fabian M Correa; Naofumi Takemoto; Vidushi Durani; Hui Liu; Justin Taylor; Noushin Farnoud; Elli Papaemmanuil; Justin R Cross; Martin S Tallman; Maria E Arcila; Mikhail Roshal; Gregory A Petsko; Bin Wu; Sung Choe; Zenon D Konteatis; Scott A Biller; John D Chodera; Craig B Thompson; Ross L Levine; Eytan M Stein
Journal:  Nature       Date:  2018-06-27       Impact factor: 69.504

9.  Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Authors:  Lynn Quek; Muriel D David; Alison Kennedy; Marlen Metzner; Michael Amatangelo; Alan Shih; Bilyana Stoilova; Cyril Quivoron; Maël Heiblig; Christophe Willekens; Véronique Saada; Samar Alsafadi; M S Vijayabaskar; Andy Peniket; Oliver A Bernard; Sam Agresta; Katharine Yen; Kyle MacBeth; Eytan Stein; George S Vassiliou; Ross Levine; Stephane De Botton; Anjan Thakurta; Virginie Penard-Lacronique; Paresh Vyas
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

10.  Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Authors:  Héléna Boutzen; Estelle Saland; Clément Larrue; Fabienne de Toni; Lara Gales; Florence A Castelli; Mathilde Cathebas; Sonia Zaghdoudi; Lucille Stuani; Tony Kaoma; Romain Riscal; Guangli Yang; Pierre Hirsch; Marion David; Véronique De Mas-Mansat; Eric Delabesse; Laurent Vallar; François Delhommeau; Isabelle Jouanin; Ouathek Ouerfelli; Laurent Le Cam; Laetitia K Linares; Christophe Junot; Jean-Charles Portais; François Vergez; Christian Récher; Jean-Emmanuel Sarry
Journal:  J Exp Med       Date:  2016-03-07       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.